Risedronate and Pamidronate Treatment in the Clinical Management of Patients with Severe Paget’s Disease of Bone and Acquired Resistance to Bisphosphonates

The aim of this study was to evaluate the efficacy and safety of risedronate and pamidronate in 30 patients (mean age = 57.86 ± 8.90 years) with severe Paget’s disease of bone (PDB), showing acquired resistance to intravenous (IV) clodronate treatment. Fifteen patients were treated with oral risedronate (30 mg/day for 8 weeks). Treatment was repeated in… CONTINUE READING